Clinical Trial Update: A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial (MOAB) at Duke University is investigating optimal atezolizumab biomarkers in recurrent glioblastoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Duke University | Conditions: Recurrent Glioblastoma | Phase 2 | Status: RECRUITING